Clinical Trial Update: Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update describing a Phase 2/Phase 3 study of daily rifapentine for latent tuberculosis infection, focusing on safety, tolerability, and effecti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Latent Tuberculosis Infection

Drugs mentioned

• Rifapentine (Priftin) (rifapentine)

Snippet

Sponsor: Centers for Disease Control and Prevention | Conditions: Latent Tuberculosis | Phase 2, Phase 3 | Status: RECRUITING